高级检索
当前位置: 首页 > 详情页

Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Obstetrics and Gynecology, Key Laboratory ofBirth Defects and Related Diseases of Women and Children ofMOE and State Key Laboratory of Biotherapy, West ChinaSecond University Hospital, Sichuan University and CollaborativeInnovation Center, Chengdu, China [2]Department of Biomedical Sciences, City University of HongKong, Kowloon Tong, Hong Kong [3]Department of Pathology, West China Second UniversityHospital, Sichuan University, Chengdu, China [4]Laboratory for Experimental Oncology and Radiobiology(LEXOR), Center for Experimental Molecular Medicine (CEMM),Academic Medical Center (AMC), University of Amsterdam,1105 AZ Amsterdam, The Netherlands [5]Center for Gastrointestinal Research and Center for TranslationalGenomics and Oncology, Baylor Scott and White ResearchInstitute and Charles A. Sammons Cancer Center, BaylorUniversity Medical Center, Dallas, TX, USA [6]Shenzhen Research Institute, City University of Hong Kong,Shenzhen, China
出处:
ISSN:

摘要:
Ovarian cancer is a heterogeneous malignancy that poses tremendous clinical challenge. Based on unsupervised classification of whole-genome gene expression profiles, four molecular subtypes of ovarian cancer were recently identified. However, single-driver molecular events specific to these subtypes have not been clearly elucidated. We aim to characterize the regulatory mechanisms underlying the poor prognosis mesenchymal subtype of ovarian cancer using a systems biology approach, involving a variety of molecular modalities including gene and microRNA expression profiles. miR-508-3p emerged as the most powerful determinant that regulates a cascade of dysregulated genes in the mesenchymal subtype, including core genes involved in epithelial-mesenchymal transition (EMT) program. Moreover, miR-508-3p down-regulation, due to promoter hypermethylation, was directly correlated with metastatic behaviors in vitro and in vivo. Taken together, our multidimensional network analysis identified miR-508-3p as a master regulator that defines the mesenchymal subtype and provides a novel prognostic biomarker to improve management of this disease.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 遗传学 2 区 生化与分子生物学 2 区 细胞生物学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 生化与分子生物学 1 区 遗传学 2 区 细胞生物学 2 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Obstetrics and Gynecology, Key Laboratory ofBirth Defects and Related Diseases of Women and Children ofMOE and State Key Laboratory of Biotherapy, West ChinaSecond University Hospital, Sichuan University and CollaborativeInnovation Center, Chengdu, China
共同第一作者:
通讯作者:
通讯机构: [2]Department of Biomedical Sciences, City University of HongKong, Kowloon Tong, Hong Kong [6]Shenzhen Research Institute, City University of Hong Kong,Shenzhen, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46666 今日访问量:3 总访问量:3332 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号